Nivolumab plus ipilimumab for hepatocellular carcinoma: a game-changer?
Dual checkpoint blockade represents an effective first-line option for selected patients with advanced HCC, offering meaningful survival benefit at the cost of increased immune-related toxicity. Future progress depends on improved patient selection, biomarker development, and rational combination strategies.
Authors
- Massimiliano Salati (ORCID: https://orcid.org/0000-0002-5579-7454)
- Lorenza Di Marco (ORCID: https://orcid.org/0000-0002-3716-7010)
- Angela Dalia Ricci (ORCID: https://orcid.org/0000-0002-0701-6764)
- Bianca Medici (ORCID: https://orcid.org/0009-0009-3349-7336)
- Yuri Maculan
- M. Dominici
- Alessandro Rizzo
- Federica Valerio
Institutions
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Istituto Tumori Bari (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Gastroenterology Hospital "Saverio de Bellis" (IT)
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1080/14712598.2026.2642273
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00